Scholarlink

Background <p>BTX A51, a first-in-class oral small molecule inhibitor of casein kinase 1α (CK1α) and cyclin-dependent kinase (CDK) 7 and 9, induces apoptosis of leukemic cells by activating p53 and inhibiting expression of <i>Mcl1.</i> Here, we report on the results of the phase 1 clinical trial of BTX A51 in patients with relapsed or refractory AML and MDS.</p> Methods <p>Adult patients with R/R AML and high-risk MDS were enrolled into eight potential doses ranging from 1 to 42&#xa0;mg dosed orally three days/week for 21 or 28&#xa0;days out of a 28-day cycle. The maximum tolerated dose, recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of BTX A51 were investigated.</p> Results <p>Thirty-one patients were enrolled and received treatment with BTX A51. Median age was 75 (range 22- 84) and 55% were male. Most patients (97%) had received prior treatment with venetoclax and hypomethylating agents. The most common treatment-emergent adverse events of any grade were nausea (67%), emesis (63%), hypokalemia (53%), and diarrhea (40%). Two patients experienced hepatic toxicity as DLTs, which resolved upon holding treatment. No treatment-related deaths occurred. The recommended phase 2 dose was 21&#xa0;mg dosed three days/week for 4&#xa0;weeks of a 28-day cycle. BTX A51 increased the expression of p53 and reduced the expression of MCL1 and RNA polymerase II phosphorylation in pre- and post-treatment immunocytochemistry studies. Overall, 3 patients (10%) experienced complete remission with incomplete count recovery (CRi). All 3 responding patients had <i>RUNX1</i> mutations and the CR/CRi rate for <i>RUNX1</i>-mutated patients receiving BTX A51 at efficacious doses (11&#xa0;mg or higher) was 30%. Ex-vivo studies confirmed higher efficacy of BTX A51 on <i>RUNX1</i>-mutated myeloblasts and demonstrated synergy with azacitidine and venetoclax.</p> Conclusions <p>Although the overall efficacy was modest, this study lays the groundwork for future studies with improved patient selection and combination approaches.</p> Trial registration <p>NCT04872166.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月15日

查看全文
  • Brian J. Ball,
  • Wenbin Xiao,
  • Gautam Borthakur,
  • Le Xuan Truong Nguyen,
  • Melissa Valerio,
  • Avanthika Venkatachalam,
  • Guido Marcucci,
  • Anthony S. Stein,
  • Dung Luong Thai,
  • David N. Cook,
  • Kyle Chan,
  • Sonali Persaud,
  • Ross L. Levine,
  • Omar Abdel-Wahab,
  • Yinon Ben-Neriah,
  • Eytan M. Stein

摘要

Background

BTX A51, a first-in-class oral small molecule inhibitor of casein kinase 1α (CK1α) and cyclin-dependent kinase (CDK) 7 and 9, induces apoptosis of leukemic cells by activating p53 and inhibiting expression of Mcl1. Here, we report on the results of the phase 1 clinical trial of BTX A51 in patients with relapsed or refractory AML and MDS.

Methods

Adult patients with R/R AML and high-risk MDS were enrolled into eight potential doses ranging from 1 to 42 mg dosed orally three days/week for 21 or 28 days out of a 28-day cycle. The maximum tolerated dose, recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of BTX A51 were investigated.

Results

Thirty-one patients were enrolled and received treatment with BTX A51. Median age was 75 (range 22- 84) and 55% were male. Most patients (97%) had received prior treatment with venetoclax and hypomethylating agents. The most common treatment-emergent adverse events of any grade were nausea (67%), emesis (63%), hypokalemia (53%), and diarrhea (40%). Two patients experienced hepatic toxicity as DLTs, which resolved upon holding treatment. No treatment-related deaths occurred. The recommended phase 2 dose was 21 mg dosed three days/week for 4 weeks of a 28-day cycle. BTX A51 increased the expression of p53 and reduced the expression of MCL1 and RNA polymerase II phosphorylation in pre- and post-treatment immunocytochemistry studies. Overall, 3 patients (10%) experienced complete remission with incomplete count recovery (CRi). All 3 responding patients had RUNX1 mutations and the CR/CRi rate for RUNX1-mutated patients receiving BTX A51 at efficacious doses (11 mg or higher) was 30%. Ex-vivo studies confirmed higher efficacy of BTX A51 on RUNX1-mutated myeloblasts and demonstrated synergy with azacitidine and venetoclax.

Conclusions

Although the overall efficacy was modest, this study lays the groundwork for future studies with improved patient selection and combination approaches.

Trial registration

NCT04872166.